Anticipatory nausea and vomiting

Does it remain a significant clinical problem?

Michael Edward Stefanek, Vivian R. Sheidler, John H. Petting

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A study performed 5 years ago in our clinic revealed a prevalence rate of 31% for anticipatory symptoms. This finding is consistent with other investigations. It was hypothesized that more effective management of postchemotherapy nausea and vomiting and briefer chemotherapy regimens since the previous study would decrease the prevalence of anticipatory symptoms. The study reported in this article assessed the prevalence of anticipatory symptoms in 121 patients receiving parenteral chemotherapy over a 7‐week period. The overall prevalence rate of 33% for anticipatory symptoms was not significantly different from the previous study or other investigations. Length of postchemotherapy nausea was significantly related to the report of anticipatory symptoms. However, the severity of symptoms reported in the investigation was mild. The prevalence in patients on adjuvant therapy for breast cancer was also significantly reduced from the previous investigation. It is concluded that although anticipatory symptoms commonly occur they are only rarely clinically significant.

Original languageEnglish (US)
Pages (from-to)2654-2657
Number of pages4
JournalCancer
Volume62
Issue number12
DOIs
StatePublished - Jan 1 1988

Fingerprint

Anticipatory Vomiting
Nausea
Drug Therapy
Vomiting
Breast Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Anticipatory nausea and vomiting : Does it remain a significant clinical problem? / Stefanek, Michael Edward; Sheidler, Vivian R.; Petting, John H.

In: Cancer, Vol. 62, No. 12, 01.01.1988, p. 2654-2657.

Research output: Contribution to journalArticle

Stefanek, Michael Edward ; Sheidler, Vivian R. ; Petting, John H. / Anticipatory nausea and vomiting : Does it remain a significant clinical problem?. In: Cancer. 1988 ; Vol. 62, No. 12. pp. 2654-2657.
@article{74e683b18a244f5497acc936cb435cc9,
title = "Anticipatory nausea and vomiting: Does it remain a significant clinical problem?",
abstract = "A study performed 5 years ago in our clinic revealed a prevalence rate of 31{\%} for anticipatory symptoms. This finding is consistent with other investigations. It was hypothesized that more effective management of postchemotherapy nausea and vomiting and briefer chemotherapy regimens since the previous study would decrease the prevalence of anticipatory symptoms. The study reported in this article assessed the prevalence of anticipatory symptoms in 121 patients receiving parenteral chemotherapy over a 7‐week period. The overall prevalence rate of 33{\%} for anticipatory symptoms was not significantly different from the previous study or other investigations. Length of postchemotherapy nausea was significantly related to the report of anticipatory symptoms. However, the severity of symptoms reported in the investigation was mild. The prevalence in patients on adjuvant therapy for breast cancer was also significantly reduced from the previous investigation. It is concluded that although anticipatory symptoms commonly occur they are only rarely clinically significant.",
author = "Stefanek, {Michael Edward} and Sheidler, {Vivian R.} and Petting, {John H.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19881215)62:12<2654::AID-CNCR2820621234>3.0.CO;2-0",
language = "English (US)",
volume = "62",
pages = "2654--2657",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Anticipatory nausea and vomiting

T2 - Does it remain a significant clinical problem?

AU - Stefanek, Michael Edward

AU - Sheidler, Vivian R.

AU - Petting, John H.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - A study performed 5 years ago in our clinic revealed a prevalence rate of 31% for anticipatory symptoms. This finding is consistent with other investigations. It was hypothesized that more effective management of postchemotherapy nausea and vomiting and briefer chemotherapy regimens since the previous study would decrease the prevalence of anticipatory symptoms. The study reported in this article assessed the prevalence of anticipatory symptoms in 121 patients receiving parenteral chemotherapy over a 7‐week period. The overall prevalence rate of 33% for anticipatory symptoms was not significantly different from the previous study or other investigations. Length of postchemotherapy nausea was significantly related to the report of anticipatory symptoms. However, the severity of symptoms reported in the investigation was mild. The prevalence in patients on adjuvant therapy for breast cancer was also significantly reduced from the previous investigation. It is concluded that although anticipatory symptoms commonly occur they are only rarely clinically significant.

AB - A study performed 5 years ago in our clinic revealed a prevalence rate of 31% for anticipatory symptoms. This finding is consistent with other investigations. It was hypothesized that more effective management of postchemotherapy nausea and vomiting and briefer chemotherapy regimens since the previous study would decrease the prevalence of anticipatory symptoms. The study reported in this article assessed the prevalence of anticipatory symptoms in 121 patients receiving parenteral chemotherapy over a 7‐week period. The overall prevalence rate of 33% for anticipatory symptoms was not significantly different from the previous study or other investigations. Length of postchemotherapy nausea was significantly related to the report of anticipatory symptoms. However, the severity of symptoms reported in the investigation was mild. The prevalence in patients on adjuvant therapy for breast cancer was also significantly reduced from the previous investigation. It is concluded that although anticipatory symptoms commonly occur they are only rarely clinically significant.

UR - http://www.scopus.com/inward/record.url?scp=0024237455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024237455&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19881215)62:12<2654::AID-CNCR2820621234>3.0.CO;2-0

DO - 10.1002/1097-0142(19881215)62:12<2654::AID-CNCR2820621234>3.0.CO;2-0

M3 - Article

VL - 62

SP - 2654

EP - 2657

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -